Kyle Doherty joined MJH Life Sciences in 2021 and is the lead editor for Oncology Fellows. He also produces print content for OncologyLive, as well as news and conference updates for OncLive.com. Email: kdoherty@mjhlifesciences.com
Eftilagimod Alpha Plus Pembrolizumab Elicits Early Efficacy Signals in Metastatic HNSCC
Frontline eftilagimod alpha plus pembrolizumab generated responses in patients with recurrent or metastatic HNSCC with negative PD-L1 expression.
Read More
International Pancreatic Cancer Screening Program Displays Practicality
The PRECEDE study demonstrated the feasibility of a large-scale early detection and prevention program for pancreatic cancer.
Enzalutamide Receives Go Ahead From European Commission in nmHSPC
The European Commission has approved enzalutamide as monotherapy and in combination with ADT in BCR nonmetastatic hormone-sensitive prostate cancer.
New Prostate Cancer Urine Test Produces Greater Diagnostic Accuracy vs Existing Tests in High-Grade Prostate Cancer
The MyProstateScore 2.0 urine test led to greater diagnostic accuracy for high-grade prostate cancer compared with existing biomarker tests.
FAK Inhibition Emerges as a Potential Complementary Treatment Pathway
Although FAK inhibition alone has displayed modest activity to date, there is interest in developing FAK-targeted therapies for combination regimens.
Functional Precision Medicine Method Aids Treatment Decision-Making in R/R Pediatric Cancers
A unique approach combining genomic and sensitivity testing with machine learning was feasible for guiding treatment selection in pediatric cancers.
Call for Boxed Warning for Secondary Malignancies on CAR T-Cell Therapies Raises Alarm, But Key Questions Remain
Experts discuss the FDA's call for a boxed warning for secondary T-cell malignancies on all approved CAR T-cell agents in late January 2024.
Richardson Discusses Implications of the FDA Withdrawal of Melflufen in Multiple Myeloma
Paul G. Richardson, MD, speaks on the FDA’s decision to withdraw the approval of melflufen plus dexamethasone in multiple myeloma.
ROSALIE Trial of EO2401/Nivolumab/Bevacizumab in Recurrent Glioblastoma Concludes
The database of the phase 1/2 trial of EO2401 in combination with nivolumab with or without bevacizumab in recurrent glioblastoma has locked.
Immunotherapy-Based Approaches Make Waves in Bladder Cancer
Experts highlight clinical trial updates in muscle-invasive bladder cancer, frontline treatment options in metastatic urothelial carcinoma, and more.
B-Cell Receptor Signaling Activity Portends Inferior Outcomes in MCL
B-cell receptor signaling characteristics were associated with worse outcomes in patients with mantle cell lymphoma.
Orca-T Proves Safe and Effective in Advanced Hematologic Malignancies
The regulatory T cell enriched donor cell agent Orca-T was safe and displayed activity in the reduced intensity conditioning setting for patients with advanced hematologic malignancies.
NICE Recommends Tisagenlecleucel for Pediatric R/R B-ALL
The National Institute for Health and Care Excellence has recommended the use of tisagenlecleucel in pediatric B-cell acute lymphoblastic leukemia.
Parsaclisib Added to Ruxolitinib Decreases Spleen Volume and Improves Symptom Scores in Myelofibrosis
Add-on parsaclisib with ruxolitinib resulted in decreased spleen volume and improved symptom assessment scores in patients with myelofibrosis.
CAN-2409 Receives FDA Orphan Drug Designation in Pancreatic Cancer
CAN-2409 has received orphan drug designation from the FDA for the treatment of patients with pancreatic cancer.
Novel CAR T-Cell Therapy HR001 Demonstrates Efficacy in R/R Non-Hodgkin Lymphoma
The novel CAR T-cell agent HR001 was effective, with durable responses and a favorable safety profile observed, in relapsed/refractory non-Hodgkin lymphoma.
Global Cancer Statistics Report Provides Insights into Cancer Incidence and Mortality
The Global Cancer Statistics, 2024, report from the American Cancer Society sheds light on worldwide cancer facts, identifying trends and making predictions for the future.
Breast-Conserving Therapy Bests Mastectomy After Preoperative Systemic Therapy in HER2+ Breast Cancer
Following preoperative systemic therapy, breast-conserving therapy led to superior OS vs mastectomy in HER2-positive breast cancer.
Copanlisib Plus Nivolumab Demonstrates Activity in Microsatellite Stable Colorectal Cancer
Copanlisib plus nivolumab was active and met the primary end point of a phase 1/2 study in a cohort of patients with MSS CRC.
Afamitresgene Autoleucel Demonstrates Efficacy in Advanced Synovial Sarcoma and Myxoid Round Cell Liposarcoma
Afami-cel displayed activity in a heavily pretreated population of patients with advanced synovial sarcoma or myxoid round cell liposarcoma.
Tiwari Highlights Updates in HER2+ and HER2-Low Breast Cancer
Shruti Tiwari, MD, discusses treatment advances in HER2-positive and HER2-low breast cancer and looks ahead to the future of the space.
Tripathy Outlines Where the HER2+ Early-Stage Breast Cancer Landscape Stands
Debu Tripathy, MD, discusses the current treatment paradigm of HER2-positive breast cancer and highlights unmet needs that remain.
NICE Endorses Cabozantinib Plus Nivolumab in Advanced RCC
NICE has recommended the combination of cabozantinib and nivolumab for adult patients with advanced renal cell carcinoma in a final draft guidance.
China’s NMPA Grants Priority Review to Sintilimab Plus Fruquintinib in pMMR/Non–MSI-H Advanced Endometrial Cancer
The new drug application for sintilimab plus fruquintinib has been granted priority review by the NMPA for pMMR/non-MSI-H advanced endometrial cancer.
Patient Insurance Status and Out-of-Pocket Costs Affect Genomic Testing Frequency
As genomic testing becomes ubiquitous in cancer care, some patients experience out-of-pocket costs that may affect oncologists’ genetic testing decisions.
Durvalumab Plus Guadecitabine Shows PFS Benefit in Cohort of Patients With ccRCC
Durvalumab in combination with guadecitabine was tolerable and led to a PFS benefit in patients with checkpoint inhibitor-naive ccRCC.
Clinicians Express Reservations Around Ethical Issues of AI in Cancer Care
A survey of practicing oncologists in the United States revealed that clinicians have ethical concerns surrounding the use of AI in cancer care.
CTL019 Plus Ibrutinib is Feasible and Effective in Relapsed/Refractory MCL
CTL019 CAR T-cell therapy plus time-limited ibrutinib resulted in high complete response rates in relapsed/refractory mantle cell lymphoma.
ASCO GI Updates Provide Window Into Evolving HCC Treatment Paradigm
Experts discuss updated findings from key clinical trials in hepatocellular carcinoma presented during the 2024 Gastrointestinal Cancers Symposium.
Japan’s MHLW Approves Zolbetuximab in CLDN18.2-Positive Gastric Cancer
The Japanese Ministry of Health, Labour and Welfare has approved zolbetuximab for CLDN18.2-positive, unresectable, advanced or recurrent gastric cancer.
IDE397 Shows Early Antitumor Activity, Safety in MTAP-Deletion Urothelial Cancer and NSCLC
RVU120 Shows Early Promise in R/R Metastatic or Advanced Solid Tumors
The WEE1 Inhibitor APR-1051 Shows Early Safety and Tolerability in Advanced, Mutated Solid Tumors
TYRA-300 Is Safe, Generates Preliminary Antitumor Activity in FGFR3+ Metastatic Urothelial Cancer